Clostridium Butyricum
Phase 3Small molecule
Clostridium Butyricum is one of 60 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.
3
Indications
7
Total Trials
5
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Fudr
PfizerPhase 3
TAS 102
Taiho Oncology, Inc.Phase 3
5-Fu
TToray Industries, Inc
Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
TQB2102
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
Calcium Levofolinate
FFujian Cancer Hospital
Phase 3
HR070803
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Leucovorin and 5-FU
AAkeso
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Probiotic Intervention1 trial
Helicobacter Pylori Eradication1 trial
Urothelial Carcinoma1 trial
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06696742·60 enrolled
Neoadjuvant Immunotherapy1 trial
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05914389·100 enrolled
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clostridium Butyricum. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details